ImCyse Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 57

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $25.9M

  • Investors
  • 16

ImCyse General Information

Description

Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines help to destroy locally the immune cells involved in the destruction of the diseased organ for the generation of a new type of T-cell called cytolytic CD4 and prevent the immunogenic responses that weaken the efficiency of chronic therapies, enabling physicians to treat and prevent severe chronic diseases caused by disruptions of the immune system.

Contact Information

Website
www.imcyse.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Drug Delivery
Biotechnology
Corporate Office
  • Avenue Pré-Aily 14
  • Angleur
  • 4031 Liege
  • Belgium
+32 04 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImCyse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 03-Feb-2021 $25.9M 000.00 00000 Completed Clinical Trials - Phase 2
7. Grant 18-Jun-2019 00.000 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 18-Jun-2019 000.00 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC 30-Nov-2017 00.000 00.000 000.00 Completed Clinical Trials - Phase 2
4. Early Stage VC 27-Aug-2014 00.000 00.000 000.00 Completed Startup
3. Early Stage VC 01-Nov-2012 00.000 00.000 000.00 Completed Startup
2. Early Stage VC 09-Feb-2011 $270K $270K 00000 Completed Startup
1. Accelerator/Incubator 01-Jan-2011 Completed Startup
To view ImCyse’s complete valuation and funding history, request access »

ImCyse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B 000,000 00.000000 000.0 000.0 00 000.0 00.000
Class E 00,000 000.00 000.00 00 000.00 0.000
Class C 000 000.00 000.00 00 000.00 0.000
Class B 000 000.00 000.00 00 000.00 0.000
Class D 00,000 00.00 00.00 00 00.00 0.000
Class C 0,000 00.00 00.00 00 00.00 0.000
Class E 000,000 000.00 000.00 00 000.00 00.000
Class B 0,000 000.00 000.00 00 000.00 0.000
Class E 39,168 $24.9 $24.9 1x $24.9 1.34%
Class C 469 $24.9 $24.9 1x $24.9 0.02%
To view ImCyse’s complete cap table history, request access »

ImCyse Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic vaccines designed to offer treatment of multiple sclerosis and diabetes. The company's vaccines
Drug Discovery
Liege, Belgium
57 As of 2023
000.00
00000 0000-00-00
00000000000 000.00

00000

ididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Cambridge, United Kingdom
000 As of 0000
00000
00.000 0000-00-00
000000&0 00000

000000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000 000000000
Cambridge, United Kingdom
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImCyse Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymab Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
Crescendo Biologics Venture Capital-Backed Cambridge, United Kingdom 00 00000 000000 - 000 00000
You’re viewing 2 of 2 competitors. Get the full list »

ImCyse Patents

ImCyse Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3222570-A1 Peptides and methods for the treatment of neuromyelitis optica Pending 29-Jun-2021 000000000
AU-2022304222-A9 Peptides and methods for the treatment of neuromyelitis optica Pending 29-Jun-2021 000000000
AU-2022304222-A1 Peptides and methods for the treatment of neuromyelitis optica Pending 29-Jun-2021 000000000
US-20240132556-A1 Peptides and methods for the treatment of neuromyelitis optica Pending 28-Jun-2021 000000000
CA-3220752-A1 Improved methods of treatment using immunogenic peptides Pending 01-Jun-2021 A61P3/10
To view ImCyse’s complete patent history, request access »

ImCyse Executive Team (15)

Name Title Board Seat Contact Info
Denis Bedoret Ph.D Chief Executive Officer
Antoon van Oosterhout Ph.D Chief Scientific Officer & Vice President, Research & Development
Vincent Carlier Ph.D Co-Founder & Research & Development Director, Immunology
Luc Elst Ph.D TecOps Director
Jean Van Rampelbergh Ph.D Chief Clinical Development Officer
You’re viewing 5 of 15 executive team members. Get the full list »

ImCyse Board Members (11)

Name Representing Role Since
Christina Franssen Ph.D Société Régionale d'Investissement de Wallonie Board Member 000 0000
Hugues Wallemacq Ph.D Noshaq Board Member 000 0000
Stefan Yee Self Board Member 000 0000
Stijn Rompay Self Board Member 000 0000
Thomas Taapken Ph.D Self Chairman of the Board 000 0000
You’re viewing 5 of 11 board members. Get the full list »

ImCyse Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImCyse Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioWin Other Minority 000 0000 000000 0
Innodia Harvest Venture Capital Minority 000 0000 000000 0
Life Sciences Research Partners Not-For-Profit Venture Capital Minority 000 0000 000000 0
Pfizer (Pharmaceuticals) Corporation Minority 000 0000 000000 0
Portail de la Wallonie Government Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

ImCyse FAQs

  • When was ImCyse founded?

    ImCyse was founded in 2010.

  • Who is the founder of ImCyse?

    Jean-Marie Saint-Remy Ph.D and Vincent Carlier Ph.D are the founders of ImCyse.

  • Who is the CEO of ImCyse?

    Denis Bedoret Ph.D is the CEO of ImCyse.

  • Where is ImCyse headquartered?

    ImCyse is headquartered in Liege, Belgium.

  • What is the size of ImCyse?

    ImCyse has 57 total employees.

  • What industry is ImCyse in?

    ImCyse’s primary industry is Drug Discovery.

  • Is ImCyse a private or public company?

    ImCyse is a Private company.

  • What is the current valuation of ImCyse?

    The current valuation of ImCyse is 00000.

  • What is ImCyse’s current revenue?

    The current revenue for ImCyse is 00000.

  • How much funding has ImCyse raised over time?

    ImCyse has raised $65.4M.

  • Who are ImCyse’s investors?

    BioWin, Innodia Harvest, Life Sciences Research Partners, Pfizer (Pharmaceuticals), and Portail de la Wallonie are 5 of 16 investors who have invested in ImCyse.

  • Who are ImCyse’s competitors?

    Kymab and Crescendo Biologics are competitors of ImCyse.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »